Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunopeptidometric assay for enzymatically active prostate-specific antigen.

Ping Wu1, Lei Zhu, Ulf-Hakan Stenman

  • 1Department of Clinical Chemistry, Helsinki University Central Hospital, FIN-00029 Helsinki, Finland. ping.wu@helsinki.fi

Clinical Chemistry
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in Prostate-Specific Antigen Testing.

Advances in clinical chemistry·2017
Same author

Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2014
Same author

Draft genome sequence of Bacillus firmus DS1.

Journal of biotechnology·2014
Same author

Treatment of distal tibial shaft fractures by three different surgical methods: a randomized, prospective study.

International orthopaedics·2014
Same author

Effect of bulk aging on surface diffusion of glasses.

The Journal of chemical physics·2014
Same author

Polarization manipulation based on electromagnetically induced transparency-like (EIT-like) effect.

Optics express·2014
Same journal

From Pooled Cohorts to PREVENT: A Perspective for Clinical Laboratorians.

Clinical chemistry·2026
Same journal

Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.

Clinical chemistry·2026
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
See all related articles

A new assay accurately detects enzymatically active prostate-specific antigen (PSA), a potential tumor marker for prostate cancer (PCa). This immunopeptidometric assay (IPMA) offers improved specificity for active PSA in patient serum.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Prostate cancer (PCa) detection can be improved by measuring specific forms of prostate-specific antigen (PSA).
  • Proteolytically active PSA is a potential tumor marker but lacks specific antibody recognition.
  • Phage display identified peptides that specifically bind active PSA.

Purpose of the Study:

  • To develop a novel assay for specifically detecting enzymatically active PSA.
  • To utilize phage-derived peptides for a new diagnostic tool.

Main Methods:

  • Developed an immunopeptidometric assay (IPMA) using PSA-capture antibodies and a PSA-binding peptide tracer.
  • Detected bound tracer using an anti-GST antibody labeled with europium chelate.
  • Assessed assay specificity using PSA isoenzymes with varying enzymatic activity.

Related Experiment Videos

Main Results:

  • The IPMA specifically detected enzymatically active PSA.
  • The assay did not detect inactive PSA forms like internally cleaved PSA and pro-PSA.
  • The IPMA detected 1-10% of free PSA in serum from prostate cancer patients.

Conclusions:

  • Phage-derived peptides enable the development of assays with high specificity for enzymatically active PSA.
  • The immunopeptidometric assay (IPMA) represents a novel assay principle with significant potential utility in diagnostics.